ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) - Research analysts at Cantor Fitzgerald raised their FY2025 earnings estimates for ADMA Biologics in a research note issued to investors on Thursday, March 20th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnology company will post earnings per share of $0.73 for the year, up from their prior forecast of $0.70. Cantor Fitzgerald has a "Overweight" rating and a $25.00 price objective on the stock. The consensus estimate for ADMA Biologics' current full-year earnings is $0.51 per share.
ADMA Biologics Stock Performance
Shares of ADMA Biologics stock traded down $0.10 during trading hours on Friday, reaching $20.22. The company had a trading volume of 2,401,540 shares, compared to its average volume of 3,368,313. The firm has a market cap of $4.78 billion, a PE ratio of 72.21 and a beta of 0.60. ADMA Biologics has a one year low of $5.90 and a one year high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The business has a fifty day simple moving average of $16.84 and a 200 day simple moving average of $18.07.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in ADMA. California State Teachers Retirement System lifted its holdings in shares of ADMA Biologics by 4.2% in the fourth quarter. California State Teachers Retirement System now owns 217,391 shares of the biotechnology company's stock worth $3,728,000 after buying an additional 8,717 shares in the last quarter. Heck Capital Advisors LLC purchased a new stake in ADMA Biologics in the 4th quarter worth approximately $225,000. Mackenzie Financial Corp boosted its holdings in ADMA Biologics by 212.2% in the 4th quarter. Mackenzie Financial Corp now owns 74,539 shares of the biotechnology company's stock valued at $1,278,000 after purchasing an additional 50,660 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of ADMA Biologics during the 4th quarter valued at $85,000. Finally, Neo Ivy Capital Management increased its holdings in shares of ADMA Biologics by 512.6% in the fourth quarter. Neo Ivy Capital Management now owns 297,627 shares of the biotechnology company's stock worth $5,104,000 after purchasing an additional 249,043 shares during the period. Institutional investors own 75.68% of the company's stock.
About ADMA Biologics
(
Get Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Featured Articles
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
